Biblio Discovery — Demo Discovery Service

20 results for "Mathijs P. Hendriks"

Showing 1–20 · 0.69 seconds · RSS

  1. Journal Article

    Diarrhoea Caused by Diffuse Metastatic Lobular Breast Cancer

    Sjoerd F. Bakker; Willem Moolenaar; Marije M. van Santen et al.

    Case Reports in Oncological Medicine, Vol. 2016 · 2016 · English · DOAJ Scopus

    A 70-year-old woman with a history of lobular breast cancer presented to our Outpatient Clinic with diarrhoea for the past 3 years. Clinical examination and laboratory research were normal. Colonoscopy showed diffuse mild erythema and a decreased vascular pattern. Biopsies from the ascending colon…

  2. Journal Article Full text

    Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival

    Arturo Moncada‐Torres; Marissa Corine van Maaren; Mathijs P. Hendriks et al.

    Scientific Reports · 2021 · English · OpenAlex Scopus

    Cox Proportional Hazards (CPH) analysis is the standard for survival analysis in oncology. Recently, several machine learning (ML) techniques have been adapted for this task. Although they have shown to yield results at least as good as classical methods, they are often disregarded because of their…

    Also available at: DOAJ

  3. Journal Article

    External validation of 87 clinical prediction models supporting clinical decisions for breast cancer patients

    Tom A. Hueting; Marissa C. van Maaren; Mathijs P. Hendriks et al.

    Breast, Vol. 69 · 2023 · English · DOAJ Scopus

    Introduction: Numerous prediction models have been developed to support treatment-related decisions for breast cancer patients. External validation, a prerequisite for implementation in clinical practice, has been performed for only a few models. This study aims to externally validate published…

  4. Journal Article

    Long-Term Colon Stent Patency for Obstructing Colorectal Cancer Combined with Bevacizumab

    Anouk E.J. Latenstein; Mathijs P. Hendriks; Emo E. van Halsema et al.

    Case Reports in Gastroenterology, Vol. 11 No. 3 · 2017 · English · DOAJ Scopus

    Self-expanding metal stents can be considered as initial treatment for malignant large bowel obstruction in the palliative setting. It is suggested that systemic anti-angiogenic therapy increases the risk of stent perforation. We report a 65-year-old woman with a metastatic, obstructing colon tumor…

  5. Journal Article Full text

    Effects and Working Mechanisms of a Multilevel Implementation Program for Applying Shared Decision-Making while Discussing Systemic Treatment in Breast Cancer

    Haske van Veenendaal; Loes J. Peters; Esther van Weele et al.

    Current Oncology, Vol. 30 No. 1 · 2022 · English · DOAJ Scopus

    Background: Enhancing the application of shared decision-making (SDM) is critical for integrating patient preferences in breast cancer treatment choices. We investigated the effect of an adapted multilevel SDM implementation program in breast cancer care. Methods: Breast cancer patients qualifying…

  6. Journal Article Full text

    Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

    Anouk W. M. A. Schaeffers; Lot A. Devriese; Carla H. van Gils et al.

    PLOS ONE, Vol. 18 No. 11 · 2023 · English · PLOS Scopus

    Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin dose limiting toxicity (CDLT) occurs often and impedes obtaining the planned cumulative cisplatin…

    Also available at: DOAJ, DOAJ

  7. Journal Article

    Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial

    Rubin J. T. Verduin; Corina J. G. van den Hurk; Ingrid S. van Maurik et al.

    BMC Cancer, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Several studies have demonstrated the efficacy of electronic patient-reported outcomes (ePROs) monitoring during chemo(immune)therapy, improving symptom detection and health-related quality of life (HRQoL). However, most existing applications only alert caregivers when patients…

  8. Journal Article Full text

    Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

    Esmée A. Dijkstra; Per J. Nilsson; Geke A.P. Hospers et al.

    Annals of Surgery · 2023 · English · OpenAlex Scopus

    OBJECTIVE: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. BACKGROUND: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3…

  9. Journal Article

    Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

    Pauline A. J. Mendelaar; Marcel Smid; Job van Riet et al.

    Nature Communications, Vol. 12 No. 1 · 2021 · English · DOAJ Scopus

    Molecular landscapes of metastatic colorectal cancers (mCRC) have often been restricted to coding regions or low numbers of patients. Here the authors present a whole-genome landscape of 429 mCRC patients, revealing the mutational impact of prior therapies and potential actionable targets.

  10. Journal Article

    PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI ‘trials within cohorts’ study

    Niven Mehra; Michiel Sedelaar; Tessa van Elst et al.

    BMJ Open, Vol. 16 No. 9 · 2026 · English · DOAJ Scopus

    Introduction The diagnostic and therapeutic landscape for high-risk localised prostate cancer and synchronous metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly evolving, driven by advances in imaging, risk stratification and systemic therapies, including the advent of precision…

  11. Journal Article

    TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment

    Sjoerd O Klaver; André N Vis; Gerard Vreugdenhil et al.

    BMJ Open, Vol. 13 No. 8 · 2023 · English · DOAJ Scopus

    Introduction The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming increasingly challenging. TripleAiM1 aims to evaluate…

  12. Journal Article

    From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

    Dianne Bosch; Kim J. M. van der Velden; Aart Beeker et al.

    Drugs - Real World Outcomes, Vol. 13 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Background In November 2020, olaparib became the first approved poly adenosine diphosphate (ADP)-ribose polymerase inhibitor (PARPi) for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations (BRCAm) in the Netherlands. As randomized clinical trials include fitter…

  13. Journal Article Full text

    Patients’ and relatives’ perspectives on the quality of end-of-Life care in advanced cancer: From the final months to bereavement

    Moyke A. J. Versluis; Yvette M. van der Linden; Lobke van Leeuwen-Snoeks et al.

    PLOS One, Vol. 21 No. 2 · 2026 · English · PLOS Scopus

    Background: End-of-life care affects both patients with advanced cancer and their relatives but is often assessed from only one perspective, namely that of bereaved relatives. This study aimed to gain insight into the quality of care as experienced by patients with advanced cancer and their…

    Also available at: DOAJ

  14. Journal Article

    Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

    Birgit S. Geurts; Thomas W. Battaglia; J. Maxime van Berge Henegouwen et al.

    BMC Cancer, Vol. 23 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP). This is a clinical study in which patients are…